N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss an update on its research & development and strategy.
In this interview Nigel talks us through the latest results and what they mean for the Company, explains how they are maintaining cell inhibition with a lower observed knockdown of the siRNA, how Nuvec will be used clinically in this space and what else investors can expect over the coming months.
N4 Pharma Plc is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines. For more information visit: https://investors.n4pharma.com/